CuraSen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- CuraSen Therapeutics's estimated annual revenue is currently $3.7M per year.
- CuraSen Therapeutics's estimated revenue per employee is $155,000
- CuraSen Therapeutics's total funding is $96M.
Employee Data
- CuraSen Therapeutics has 24 Employees.
- CuraSen Therapeutics grew their employee count by 14% last year.
CuraSen Therapeutics's People
| Name | Title | Email/Phone |
|---|
CuraSen Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is CuraSen Therapeutics?
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson's Disease, Alzheimer's Disease and less common neurodegenerative disorders. The company is developing small molecule drugs targeting a novel mechanism in the brain to modify disease pathology, and alleviate disabling symptoms, such as cognition, executive function, and motor and autonomic dysfunction, all of which can severely impact quality of life. CuraSen's drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration.
keywords:N/A
$96M
Total Funding
24
Number of Employees
$3.7M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Mateo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 24 | N/A | N/A |
#2 | $2.8M | 24 | 380% | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $2.4M | 24 | N/A | N/A |
#5 | $3.4M | 24 | 33% | $13M |